Guinea-pig firms to test interim UK value-based pricing in 2014
This article was originally published in Scrip
Executive Summary
Some clarity is finally emerging on how the main UK health technology appraisal body NICE will incorporate ‘value-based pricing’ into its decisions. According to a source close to the ongoing but secretive talks, the first NICE appraisals incorporating VBP will take place in June 2014. It is also likely there will be a 6-month “interim process” designed by NICE during which a few companies will work through the VBP process. This interim system will be in place January 2014, allowing the UK government to keep its pledge to launch a new pricing system by the beginning of next year.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.